Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Ecopipam with UGT Inhibitors in Healthy Subjects
NCT04902105Phase 1Completed
- Sponsor
- Emalex Biosciences
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ecopipam in Tourette syndrome (TS), sponsored by Emalex Biosciences. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve from Zero to Infinity and 1 more. Started May 2021; status: completed.
02
Drugs
ecopipam
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT04902105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04902105.